🇺🇸 FDA
Pipeline program

CT-95

CNTX-CT95-101

Phase 1 small_molecule active

Quick answer

CT-95 for Mesothelin-Expressing Tumors is a Phase 1 program (small_molecule) at Context Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Context Therapeutics
Indication
Mesothelin-Expressing Tumors
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials